Emad Roshdy Bassaly, MD | |
1725 Mendon Rd, Suite 203, Cumberland, RI 02864-4337 | |
(401) 333-6100 | |
(401) 333-6109 |
Full Name | Emad Roshdy Bassaly |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 1725 Mendon Rd, Cumberland, Rhode Island |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1508957200 | NPI | - | NPPES |
0138967 | Medicaid | MA | |
110003241A | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207LP2900X | Anesthesiology - Pain Medicine | MD10521 (Rhode Island) | Primary |
207L00000X | Anesthesiology | 46332 (Massachusetts) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Emad Roshdy Bassaly, MD 197 Church Pond Drive, Tiverton, RI 02878 Ph: (401) 624-1997 | Emad Roshdy Bassaly, MD 1725 Mendon Rd, Suite 203, Cumberland, RI 02864-4337 Ph: (401) 333-6100 |
News Archive
Adolescents with depression who were treated with interpersonal psychotherapy (IPT-A) had significantly better outcomes when their therapists regularly assessed depression symptoms and augmented treatment for insufficient responders after four weeks of therapy rather than waiting until Week 8, reports a study published in the January 2019 issue of the Journal of the American Academy of Child and Adolescent Psychiatry
A new study entitled The Economic Footprint of the Pharmaceutical Industry – Regional breakdown and differentiation between originators and generics, independently conducted by WifOR reveals how the pharmaceutical industry, one of the world's largest industries, plays a major role in boosting the global economy across regions.
Humans are exposed to a variety of toxins and chemicals every day. According to the epithelial barrier hypothesis, exposure to many of these substances damages the epithelium, the thin layer of cells that covers the surface of our skin, lungs and intestine. Defective epithelial barriers have been linked to a rise in almost two billion allergic, autoimmune, neurodegenerative and psychiatric diseases.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).
The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition.
› Verified 6 days ago
Dr. George Nmi Kortyna, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1725 Mendon Rd, Cumberland, RI 02864 Phone: 401-333-6100 Fax: 401-333-6900 |